Full Text:   <627>

Summary:  <818>

CLC number: R511

On-line Access: 2020-12-09

Received: 2020-04-17

Revision Accepted: 2020-10-22

Crosschecked: 2020-11-11

Cited: 0

Clicked: 1404

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Yong-zheng Guo

https://orcid.org/0000-0003-4981-8957

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2020 Vol.21 No.12 P.948-954

http://doi.org/10.1631/jzus.B2000204


Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China


Author(s):  Yong-zheng Guo, Kai-jin Xu, Yong-tao Li, Jia-dan Fu, Min Xu, Ling Yu, Ji-fang Sheng, Biao Zhu

Affiliation(s):  Department of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

Corresponding email(s):   zhubiao1207@zju.edu.cn

Key Words:  SARS-CoV, Lopinavir, Darunavir, Pneumonia, Lipid metabolism


Yong-zheng Guo, Kai-jin Xu, Yong-tao Li, Jia-dan Fu, Min Xu, Ling Yu, Ji-fang Sheng, Biao Zhu. Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China[J]. Journal of Zhejiang University Science B, 2020, 21(12): 948-954.

@article{title="Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China",
author="Yong-zheng Guo, Kai-jin Xu, Yong-tao Li, Jia-dan Fu, Min Xu, Ling Yu, Ji-fang Sheng, Biao Zhu",
journal="Journal of Zhejiang University Science B",
volume="21",
number="12",
pages="948-954",
year="2020",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2000204"
}

%0 Journal Article
%T Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China
%A Yong-zheng Guo
%A Kai-jin Xu
%A Yong-tao Li
%A Jia-dan Fu
%A Min Xu
%A Ling Yu
%A Ji-fang Sheng
%A Biao Zhu
%J Journal of Zhejiang University SCIENCE B
%V 21
%N 12
%P 948-954
%@ 1673-1581
%D 2020
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2000204

TY - JOUR
T1 - Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China
A1 - Yong-zheng Guo
A1 - Kai-jin Xu
A1 - Yong-tao Li
A1 - Jia-dan Fu
A1 - Min Xu
A1 - Ling Yu
A1 - Ji-fang Sheng
A1 - Biao Zhu
J0 - Journal of Zhejiang University Science B
VL - 21
IS - 12
SP - 948
EP - 954
%@ 1673-1581
Y1 - 2020
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2000204


Abstract: 
The aim of this study was to evaluate the safety of an antiviral regimen of protease inhibitors combined with Arbidol (umifenovir) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia patients. The genomic sequence of SARS-CoV-2 is highly homologous to that of SARS-CoV (Zhou et al., 2020). Previously published basic and clinical research on anti-SARS-CoV treatment found that lopinavir/ritonavir (LPV/r) could improve the prognosis of SARS patients (Chan et al., 2003; Chu et al., 2004). darunavir (DRV) is another protease inhibitor that blocks the binding of SARS-CoV-2 to human angiotensin-converting enzyme 2 (Omotuyi et al., 2020). The broad-spectrum antiviral drug Arbidol (umifenovir) also shows in vitro anti-SARS-CoV activity (Khamitov et al., 2008).

蛋白酶抑制剂联合阿比多尔的抗病毒方案在浙江省SARS-CoV-2肺炎患者中的安全性研究

目的:评价蛋白酶抑制剂联合阿比多尔的抗病毒方案在严重急性呼吸综合征冠状病毒2(SARS-CoV-2)肺炎患者中应用的安全性.
创新点:首次评价了蛋白酶抑制剂联合阿比多尔的抗病毒方案在SARS-CoV-2肺炎患者中安全性良好.
方法:回顾性分析了52例SARS-CoV-2肺炎患者的临床资料,分析患者入院时以及抗病毒治疗期间症状、肝功能及血脂水平等的变化.
结论:该方案最常见的不良反应为消化道症状和血脂代谢异常,血清甘油三酯、总胆固醇和低密度脂蛋白胆固醇水平均较治疗前显著升高;与洛匹那韦/利托那韦相比,达芦那韦/考比司他对血脂代谢的负面影响较小;建议对使用蛋白酶抑制剂联合阿比多尔抗病毒方案的患者密切监测和随访血脂水平变化.

关键词:严重急性呼吸综合征冠状病毒2(SARS-CoV-2);洛匹那韦;达芦那韦;肺炎;血脂代谢

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Banhegyi D, Katlama C, da Cunha CA, et al., 2012. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN. Curr HIV Res, 10(2):171-181.

[2]Chan KS, Lai ST, Chu CM, et al., 2003. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J, 9(6):399-406.

[3]Chu CM, Cheng VCC, Hung IFN, et al., 2004. Role of lopinavir/ ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax, 59(3):252-256.

[4]Huang XJ, Xu LM, Sun LJ, et al., 2019. Six-year immunologic recovery and virological suppression of HIV patients on LPV/r-based second-line antiretroviral treatment: a multi-center real-world cohort study in China. Front Pharmacol, 10:1455.

[5]Khamitov RA, Loginova SI, Shchukina VN, et al., 2008. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol, 53(4):9-13.

[6]National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), 2002. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 106(25):3143-3421.

[7]National Health Commission of the People’s Republic of China, 2020. Diagnosis and treatment of novel coronavirus pneumonia (Trial Version 7) (in Chinese). http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml [Accessed on Mar. 11, 2020].

[8]Omotuyi OI, Nash O, Ajiboye BO, et al., 2020. Darunavir disrupts critical nodes in metastable 2019-nCoV-RBD/ ACE-2 complex. Preprints, 2020030125.

[9]https://doi.org/10.20944/preprints202003.0125.v1

[10]Orkin C, DeJesus E, Khanlou H, et al., 2013. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med, 14(1):49-59.

[11]Ortiz R, Dejesus E, Khanlou H, et al., 2008. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS, 22(12):1389-1397.

[12]Ramshanker N, Jessen N, Voss TS, et al., 2019. Effects of short-term prednisolone treatment on indices of lipolysis and lipase signaling in abdominal adipose tissue in healthy humans. Metabolism, 99:1-10.

[13]Wang MZ, Cai BQ, Li LY, et al., 2004. Efficacy and safety of Arbidol in treatment of naturally acquired influenza. Acta Acad Med Sin, 26(3):289-293 (in Chinese).

[14]Xu KJ, Cai HL, Shen YH, et al., 2020. Management of COVID-19: the Zhejiang experience. J Zhejiang Univ (Med Sci), 49(2):147-157 (in Chinese).

[15]Xu XW, Wu XX, Jiang XG, et al., 2020. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. BMJ, 368:m606.

[16]Zhou P, Yang XL, Wang XG, et al., 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798):270-273.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - Journal of Zhejiang University-SCIENCE